Foundayo vs. Wegovy vs. Zepbound: The First Three-Way GLP-1 Comparison
For the first time, patients choosing a GLP-1 for weight loss have three genuinely competitive options from two pharmaceutical giants. Here's how they compare across every dimension that matters.
The Three Contenders at a Glance
| Feature | Wegovy | Zepbound | Foundayo |
|---|---|---|---|
| Generic Name | Semaglutide | Tirzepatide | Orforglipron |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Available Formats | Weekly injection + Daily pill | Weekly injection | Daily pill |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist | GLP-1 small-molecule agonist |
| Peak Weight Loss | ~15–17% (injection/pill) | ~21–23% (SURMOUNT) | ~12.4% (ATTAIN-1) |
| Self-Pay Price | $149–$349/mo | $299–$449/mo | From $149/mo |
| Food Restrictions | Pill: 30-min empty stomach | None | None |
| Cardiovascular Data | Yes (SELECT trial) | Partial (SURPASS-CVOT ongoing) | No outcome data yet |
| FDA Approved | 2021 (injection), Dec 2025 (pill) | Nov 2023 | April 1, 2026 |
Weight Loss: How the Numbers Stack Up
Zepbound delivers the largest weight loss of any single-agent GLP-1 currently approved. In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight at 72 weeks. That's roughly 52 pounds for someone starting at 230.
Wegovy's injectable form (2.4 mg weekly) produced about 15% weight loss in the STEP 1 trial at 68 weeks. The new Wegovy pill (oral semaglutide 25 mg daily) showed approximately 16.6% weight loss in the OASIS 4 trial — impressively comparable to the injection.
Foundayo is the newcomer. The ATTAIN-1 trial showed 12.4% weight loss at the highest dose (36 mg) over 72 weeks for patients who stayed on treatment. That's meaningful — roughly 27 pounds from a baseline of 230 — but notably less than both Wegovy and Zepbound at their best.
Price Comparison: The Full Picture
| Scenario | Wegovy | Zepbound | Foundayo |
|---|---|---|---|
| Starting dose (self-pay) | $149/mo (pill) or $199/mo (injection, first 2 mo) | $299/mo (2.5 mg vial) | From $149/mo |
| Maintenance dose | $299/mo (25 mg pill) or $349/mo (injection) | $449/mo (7.5 mg+ vial) | TBD at higher doses |
| With commercial insurance | As low as $25/mo | As low as $25/mo | As low as $25/mo |
| Medicare Part D (July 2026) | $50/mo | $50/mo | $50/mo |
The price advantage once enjoyed by compounded options has narrowed dramatically. At $149/mo for starting doses of either Wegovy pill or Foundayo, brand-name oral GLP-1s are now competitive with many compounding telehealth programs.
Side Effects: What to Expect
All three medications share the classic GLP-1 side-effect profile: nausea, vomiting, diarrhea, and constipation. These are typically worst during the dose-escalation period and improve over time.
Foundayo's key selling point here is early data suggesting it may be better tolerated at higher doses than injectable GLP-1s, though head-to-head comparisons are limited. All three carry the same boxed warning regarding thyroid C-cell tumors seen in rodent studies.
Who Should Choose What
Choose Zepbound if: Maximum weight loss is your priority and you're comfortable with weekly injections. The dual GLP-1/GIP mechanism produces the most weight loss of any currently available single agent.
Choose Wegovy pill if: You want an oral option with the longest safety track record and cardiovascular outcome data (SELECT trial). You don't mind the 30-minute empty-stomach requirement.
Choose Foundayo if: You want the simplest oral option (no food restrictions, any time of day) and moderate weight loss is acceptable. Especially compelling if you're needle-averse and find the Wegovy pill's food restrictions burdensome.